9 unknown, 3 recruiting. 9 Phase 1, 9 Phase 2, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Unknown 7, Recruiting 2 |
| Phase 2 | 9 | Unknown 8, Recruiting 1 |
| Early Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow Antigens, CD19: new trials by email Literature Review of Antigens, CD19 trials Research Report on Antigens, CD19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RN1201 Injection in the Treatment of Antibody-Mediated Diseases CD19 and BCMA-targeted allogeneic CAR-T cells - Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 9 | 2025-07-07 | 2026-06-12 |
| Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases CD19 or CD19-BCMA CAR-T - SLE (Systemic Lupus), Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 20 | 2024-09-14 | 2026-03-06 |
| Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma CD19 and CD22 targeted CAR-T cells - Lymphoma, B-Cell | Phase 1 / Phase 2 | Unknown | Kecellitics Biotech Company Ltd | 50 | 2022-12-10 | 2022-12-14 |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma CD19 and CD22 targeted prime CAR- T cells - B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Chongqing Precision Biotech Co., Ltd | 40 | 2021-05-23 | 2023-04-18 |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL CD19 and CD22 targeted prime CAR-T cells - B-ALL | Phase 1 / Phase 2 | Recruiting | Chongqing Precision Biotech Co., Ltd | 40 | 2021-03-07 | 2025-02-25 |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma CD19 and CD22 targeted CAR-T cells - Leukemia, B-cell, Lymphoma, B-Cell | Phase 1 / Phase 2 | Unknown | Chongqing Precision Biotech Co., Ltd | 40 | 2020-08-25 | 2023-04-18 |
| CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL CD19 and CD22 targeted CAR-T cells - B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Early Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 30 | 2020-05-01 | 2020-03-11 |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma CD19 and CD22 targeted CAR-T cells - Leukemia, B-cell, Lymphoma, B-Cell | Phase 1 / Phase 2 | Unknown | Chongqing Precision Biotech Co., Ltd | 40 | 2019-09-01 | 2023-04-18 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies CD19 or CD20 CAR T cells briging HSCT - Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Unknown | Southwest Hospital, China | 100 | 2016-07-01 | 2016-09-07 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Lymphoma, Large B-Cell, Diffuse (4) · Leukemia, Prolymphocytic, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, B-Cell (2) · Lymphoma (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Lupus Erythematosus, Systemic (1) · Myositis (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Recurrence (1)
Chongqing Precision Biotech Co., Ltd (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · Kecellitics Biotech Company Ltd (1) · Nanjing Bioheng Biotech Co., Ltd. (1) · Southwest Hospital, China (1) · The First Affiliated Hospital of Soochow University (1) · Xinqiao Hospital of Chongqing (1)
China (12)
Cheng Qian, PhD (4) · Sanbin Wang, MD (3) · Jieping Chen, MD,PhD (1) · Lin Yang, Ph.D. (1) · Xi Zhang, MD phD (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1)